Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
10 participants
INTERVENTIONAL
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vepoloxamer - Low dose
Vepoloxamer injection administered intravenously 225 mg/kg over 3 hours
Vepoloxamer
Vepoloxamer - High dose
Vepoloxamer injection administered intravenously 450 mg/kg over 3 hours
Vepoloxamer
5% dextrose in water (D5W)
D5W administered intravenously over 3 hours
5% dextrose in water
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vepoloxamer
5% dextrose in water
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Duration of documented heart failure \>3 months
* On stable concomitant medication regimen ≥4 weeks
* Left ventricular ejection fraction ≤35%
* Systolic blood pressure ≥90 mmHg
Exclusion Criteria
* History of myocardial infarction, coronary artery bypass graft surgery, or percutaneous intervention within the prior 3 months
* Estimated glomerular filtration rate ≤45 mL/min/1.73 m2
* Acutely decompensated heart failure within 1 month prior to the screening visit
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mast Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edwin L. Parsley, D.O.
Role: STUDY_DIRECTOR
Mast Therapeutics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Center
Detroit, Michigan, United States
Research Center
Tupelo, Mississippi, United States
Research Center
Cardiff, New South Wales, Australia
Research Center
Melbourne, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MST-188-09
Identifier Type: -
Identifier Source: org_study_id